JOEL BYRON NELSON
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD069351L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15232
Professional information
Dr. Joel B Nelson, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Urology
Address:
Univ Of Pittsburgh Phys Urology
5200 Centre Ave SUITE 209, Pittsburgh 15232
(412) 692-4100 (Phone)
5200 Centre Ave SUITE 209, Pittsburgh 15232
(412) 692-4100 (Phone)
Certifications:
Urology, 2008
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Northwestern Center Feinberg School of Medicine
Graduated: 1988
Northwestern Center Feinberg School of Medicine
Graduated: 1988
Joel Nelson, Pittsburgh PA
Work:
Department of Urology
5200 Centre Ave, Pittsburgh, PA 15232
5200 Centre Ave, Pittsburgh, PA 15232
Joel B Nelson, Pittsburgh PA
Specialties:
Urologist
Address:
5200 Centre Ave, Pittsburgh, PA 15232
3471 5Th Ave, Pittsburgh, PA 15213
3471 5Th Ave, Pittsburgh, PA 15213
Board certifications:
American Board of Urology Certification in Urology
Methods For Diagnosing Prostate Cancer And Predicting Prostate Cancer Relapse
US Patent:
2013007, Mar 28, 2013
Filed:
Sep 14, 2012
Appl. No.:
13/619556
Inventors:
Jianhua Luo - Wexford PA, US
George Konstantine Michalopoulos - Pittsburg PA, US
Joel Byron Nelson - Pittsburgh PA, US
Chi Song - New Haven CT, US
Chien-Cheng Tseng - Pittsburgh PA, US
Yanping Yu - Wexford PA, US
George Konstantine Michalopoulos - Pittsburg PA, US
Joel Byron Nelson - Pittsburgh PA, US
Chi Song - New Haven CT, US
Chien-Cheng Tseng - Pittsburgh PA, US
Yanping Yu - Wexford PA, US
International Classification:
C12Q 1/68
US Classification:
506 9
Abstract:
The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.